Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis
Status:
Not yet recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical
study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week
maintenance treatment period, and an 8-week safety follow-up period. It is planned to include
111 adult subjects with psoriatic arthritis.